acut
exacerb
chronic
bronchiti
aecb
import
caus
death
morbid
develop
countri
also
signific
econom
impact
diseas
character
increas
dyspnoea
sputum
volum
sputum
purul
commonli
associ
pathogen
haemophilu
inzuenza
streptococcu
pneumonia
moraxella
catarrhali
h
injluenza
pneumonia
express
virul
determin
directli
indirectli
impair
mucociliari
clearanc
incit
consequ
permiss
microbi
persist
regard
use
antibiot
current
lack
largescal
clinic
trial
suffici
power
provid
good
evidencebas
inform
nonetheless
antimicrobi
chemotherapi
repeatedli
shown
confer
benefit
patient
moder
sever
featur
aecb
simpl
clinic
criteria
use
identifi
patient
higher
likelihood
treatment
failur
mortal
aecb
includ
signific
cardiopulmonari
comorbid
frequent
exacerb
advanc
declin
lung
function
malnutrit
gener
debil
advanc
age
year
concurr
treatment
corticosteroid
patient
aggress
antimicrobi
approach
aecb
may
warrant
order
prevent
clinic
failur
represent
clinic
perspect
appropri
drug
includ
stabl
blactamas
bactericid
caus
pathogen
penetr
diseas
lung
tissu
high
concentr
good
safeti
profil
topic
review
infect
acut
exacerb
chronic
bronchiti
clinic
perspect
introduct
chronic
obstruct
pulmonari
diseas
copd
character
irrevers
airflow
obstruct
due
chronic
bronchiti
emphysema
defin
ratio
forc
expiratori
volum
set
forc
vital
capac
fevi
fvc
less
patient
subject
acut
exacerb
acut
declin
fev
often
associ
increas
dyspnoea
product
increas
quantiti
sputum
may
purul
recent
epidemiolog
data
usa
show
copd
affect
estim
million
individu
fifth
common
caus
death
develop
respiratori
failur
acut
exacerb
copd
occur
whose
stabl
airway
function
sever
impair
howev
respiratori
failur
caus
death
group
acut
exacerb
copd
also
result
death
due
caus
acut
myocardi
infarct
role
infect
aecb
contenti
issu
bacteria
neutrophil
frequent
identifi
sputum
patient
aecb
unclear
whether
causal
relationship
develop
exacerb
whether
bacteri
count
mere
allow
increas
result
acut
impair
mucociliari
clearanc
studi
antibiot
reveal
posit
small
effect
compar
placebo
patient
aecb
interest
target
therapi
need
data
allow
us
identifi
patient
benefit
antimicrobi
therapi
other
probabl
mandatori
compon
manag
within
trachea
bronchi
medium
small
airway
lung
respiratori
mucosa
normal
steril
evolut
copd
individu
patient
gradual
increas
mucu
product
depress
ciliari
function
epitheli
cell
injuri
bacteria
normal
present
airway
larynx
abl
colon
diseas
epithelium
associ
purul
sputum
chronic
bronchiti
haemophilu
influenza
streptococcu
pneumonia
convincingli
demonstr
may
pathogen
cours
common
colon
upper
respiratori
tract
recov
lower
airway
even
c
harcourt
publish
ltd
r
c
read
stabl
copd
monso
et
al
perform
bronchoscop
sampl
protect
specimen
brush
psb
lower
airway
outpati
stabl
copd
compar
patient
acut
exacerb
copd
show
preval
lower
airway
bacteri
colon
outpati
stabl
copd
high
mainli
due
h
infruenza
pneumonia
whilst
exacerb
copd
associ
higher
yield
pathogen
higher
number
organ
patient
sever
aecb
psb
retriev
wider
rang
bacteria
includ
gramneg
enter
bacilli
pseudomona
sp
stenotrophomona
sp
therefor
least
even
infect
bacteri
pathogen
caus
acut
exacerb
clearli
flourish
lower
airway
patient
associ
inflammatori
infiltr
evidenc
yield
neutrophil
sputum
molecular
type
strain
h
influenza
isol
sputum
patient
copd
demonstr
singl
strain
may
persist
mani
month
within
lower
respiratori
tract
mucosa
patient
remain
present
even
acut
exacerb
copd
treat
antibiot
suggest
haemophilu
infuenza
exist
state
equilibrium
host
defenc
lost
exacerb
antimicrobi
therapi
equilibrium
restor
though
microb
erad
chronic
colon
like
constant
balanc
act
host
bacteri
colon
one
hand
host
defenc
includ
cough
ciliari
beat
mucu
contain
secret
immunoglobulin
lactoferrin
alveolar
macrophag
hand
microb
adapt
avoid
rapid
clearanc
gain
nutrient
surviv
respiratori
tract
suffici
grow
dissemin
host
case
haemophilu
injluenza
factor
enabl
organ
achiev
aim
includ
product
polysaccharid
capsul
pili
lipopolysaccharid
outer
membran
protein
ironregul
protein
factor
toxic
ciliari
activ
review
read
finch
pathogen
associ
exacerb
copd
summar
ball
summari
bacteria
present
within
lower
airway
patient
stabl
copd
case
aecb
evid
increas
inflamm
lower
airway
togeth
increas
bacteri
number
whether
latter
caus
effect
elucid
tabl
studi
assess
metaanalysi
differ
term
main
outcom
measur
symptom
score
day
ill
etc
abl
report
crude
overal
effect
size
rel
placebo
effect
peak
expiratori
flow
pef
report
major
studi
overal
metaanalysi
demonstr
modest
statist
signific
benefit
antibiot
therapi
overal
effect
size
compar
placebo
ci
peak
expiratori
flow
improv
small
amount
min
compar
placebo
none
studi
assess
includ
qualiti
life
outcom
largest
studi
assess
anthonisen
et
al
stratifi
patient
accord
sever
ill
abl
demonstr
largest
effect
size
patient
sever
exacerb
antibiot
gave
greatest
benefit
term
resolut
symptom
avoid
deterior
patient
two
follow
featur
increas
dyspnoea
increas
sputum
volum
increas
sputum
purul
europ
commonest
antimicrobi
use
aecb
includ
aminopencillin
uk
franc
macrolid
spain
tetracyclin
germani
third
gener
cephalosporin
itali
european
respiratori
societi
american
thorac
societi
produc
guidelin
manag
copd
endors
judici
use
simpl
inexpens
antimicrobi
therapi
base
individu
clinic
assess
physician
british
thorac
societi
recommend
antibiot
therapi
two
worsen
dyspnoea
increas
sputum
volum
increas
sputum
purul
present
major
pathogen
haemophilu
injeuenza
demonstr
rise
resist
aminopenicillin
mainli
due
product
plactamas
uk
preval
resist
h
infuenza
rang
major
lactamas
plasmidmedi
transfer
preval
expect
rise
increas
use
aminopenicillin
commun
erythromycin
virtual
activ
haemophilu
injluenza
clarithromycin
better
activ
though
base
studi
demonstr
h
influenza
isol
mic
pg
ml
less
azithromycin
better
vitro
activ
macrolid
moraxella
catarrhali
demonstr
almost
univers
product
plactamas
also
resist
trimethoprim
review
amy
gemmel
resist
plactam
amongst
streptococcu
pneumonia
isol
due
stepwis
mutat
penicillinbind
protein
controversi
regard
impact
penicillin
resist
pneumococci
manag
patient
respiratori
tract
infect
patient
pneumonia
treat
high
dose
penicillin
subsequ
shown
infect
penicillinresist
pneumococci
show
increas
sever
outcom
compar
patient
sensit
strain
howev
effect
penicillin
resist
amongst
pneumococci
outcom
communitytr
aecb
lower
dose
oral
agent
gener
use
investig
pneumococc
resist
associ
childcar
facil
hospit
facil
antibiot
use
immunocompromis
importantli
longterm
treatment
low
dose
plactam
antibiot
recent
shown
contribut
select
pressur
promot
pharyng
carriag
penicillinresist
strain
pneumoniu
potenti
implic
patient
aecb
treat
commun
obviou
identifi
patient
like
benefit
antibiot
therapi
regard
patient
present
gener
practition
cough
possibl
identifi
patient
benefit
accru
use
antibiot
includ
patient
acut
bronchiti
otherwis
good
respiratori
health
recent
metaanalysi
doubleblind
placebocontrol
trial
antibiot
patient
present
acut
cough
demonstr
neither
resolut
cough
clinic
improv
significantli
hasten
antibiot
therapi
regard
patient
copd
trial
anthonisen
et
al
show
patient
two
increas
dyspnoea
ii
increas
sputum
volum
iii
increas
sputum
purul
benefit
antibiot
therapi
whilst
patient
one
featur
unlik
benefit
heterogen
popul
possibl
posit
benefit
antibiot
sever
subgroup
dilut
studi
antibiot
therapi
patient
aecb
major
patient
present
commun
physician
aecb
fulfil
simpl
clinic
criteria
therefor
unlik
benefit
antimicrobi
therapi
strong
case
target
antibiot
therapi
patient
sever
manifest
aecb
major
determin
surviv
longterm
patient
aecb
age
degre
airway
obstruct
fevi
coexist
cardiopulmonari
diseas
ischaem
heart
diseas
also
diabet
link
poor
outcom
copd
patient
use
oral
corticosteroid
also
link
poor
outcom
seneff
et
al
demonstr
amongst
patient
admit
intens
care
unit
aecb
variabl
associ
hospit
mortal
includ
age
sever
respiratori
nonrespiratori
organ
system
dysfunct
hospit
length
stay
intens
care
unit
icu
admiss
factor
impli
wors
prognosi
infect
aecb
although
factor
associ
poorer
outcom
copd
effect
necessarili
mediat
infect
prescott
et
al
investig
patient
die
aecb
determin
whether
death
directli
link
infect
clinic
ground
histor
risk
factor
associ
infect
death
presenc
chronic
mucu
hypersecret
despit
reserv
strong
argument
target
therapi
patient
manifest
diseas
associ
poor
prognosi
made
futur
studi
determin
whether
use
antimicrobi
therapi
patient
affect
clinic
outcom
qualiti
life
measur
likelihood
hospit
admiss
import
econom
term
qualiti
life
failur
outpati
manag
result
patient
need
return
physician
one
studi
determin
patient
identifi
coexist
cardiopulmonari
diseas
histori
recurr
exacerb
per
year
greatest
risk
fail
therapi
need
return
visit
appropri
antimicrobi
therapi
patient
aecb
tabl
suggest
appropri
antimicrobi
therapi
patient
aecb
major
patient
present
gener
practition
requir
antibiot
therapi
patient
acut
bronchiti
simpl
chronic
bronchiti
reason
lung
function
less
two
three
anthonisen
criteria
patient
ambul
rel
well
coexist
ill
present
two
anthonisen
criteria
probabl
manag
simpl
therapi
lactam
exampl
aminopenicillin
cheap
like
efficaci
group
howev
local
data
may
point
high
preval
filactamasesecret
h
injkenza
case
therapi
antibiot
stabl
plactamas
logic
includ
coamoxiclav
quinolon
modern
macrolid
clarithromycin
azithromycin
patient
advanc
age
cardiopulmonari
comorbid
moder
sever
impair
lung
function
fevi
would
seem
logic
treat
infect
sophist
antibiot
order
ensur
microbiolog
clearanc
particularli
patient
recurr
exacerb
infect
plactamasesecret
h
injiuenza
like
addit
patient
like
infect
unusu
pathogen
gramneg
enterobacteriacea
staphylococcu
aureu
patient
use
advanc
antimicrobi
coamoxiclav
quinolon
modern
macrolid
would
seem
logic
current
evid
basi
trial
determin
whether
effect
clinic
outcom
conduct
though
argu
difficult
